Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ResMed Inc. reported revenue of $5.15B, up 9.8% year over year. Operating margin was 32.7% and net margin 27.2%, on a free-cash-flow margin of 32.3% with capital expenditure at 1.7% of revenue. Every figure is computed directly from RMD's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $5.15B | 32.7% | 27.2% |
| FY2024 | $4.69B | 28.2% | 21.8% |
| FY2023 | $4.22B | 26.8% | 21.3% |
| FY2022 | $3.58B | 28.0% | 21.8% |
| FY2021 | $3.20B | 28.3% | 14.8% |
How does RMD compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.